BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sacco R, Mismas V, Romano A, Bertini M, Bertoni M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Giacomelli L, Marceglia S, Bargellini I. Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients. World J Hepatol 2015; 7(1): 33-39 [PMID: 25624994 DOI: 10.4254/wjh.v7.i1.33]
URL: https://www.wjgnet.com/1948-5182/full/v7/i1/33.htm
Number Citing Articles
1
A. Darnell, E. Belmonte, M. Reig, C. Brú. Evaluación postratamiento locorregional y sistémico del carcinoma hepatocelularRadiología 2018; 60(5): 424 doi: 10.1016/j.rx.2018.05.004
2
S. Moalla, M. Nadjawi, N. Lassau. Évaluation de la réponse thérapeutique en échographie de contrasteJournal d'imagerie diagnostique et interventionnelle 2018; 1(1): 25 doi: 10.1016/j.jidi.2017.10.003
3
Alireza Mohseni, Azarakhsh Baghdadi, Seyedeh Panid Madani, Haneyeh Shahbazian, Mohammad Mirza-Aghazadeh-Attari, Ali Borhani, Shadi Afyouni, Ghazal Zandieh, Marina Baretti, Amy K. Kim, Mark Yarchoan, Ihab R. Kamel. Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parametersAbdominal Radiology 2024; 49(8): 2595 doi: 10.1007/s00261-024-04257-0
4
Hyunsoo Kim, Su Jong Yu, Injun Yeo, Young Youn Cho, Dong Hyeon Lee, Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Sungyoung Lee, Jongsoo Jun, Taesung Park, Jung-Hwan Yoon, Youngsoo Kim. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS)Molecular & Cellular Proteomics 2017; 16(7): 1312 doi: 10.1074/mcp.M116.066704
5
Luzie A. Doemel, Julius Chapiro, Fabian Laage Gaupp, Lynn Jeanette Savic, Ahmet S. Kucukkaya, Alexandra Petukhova, Jonathan Tefera, Tal Zeevi, MingDe Lin, Todd Schlachter, Ariel Jaffe, Mario Strazzabosco, Timil Patel, Stacey M. Stein. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRIEuropean Radiology 2021; 31(5): 2737 doi: 10.1007/s00330-020-07381-9
6
Mehran Afshar, Peter Fletcher, Antonio D Bardoli, Yuk Ting Ma, Pankaj Punia. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohortOncotarget 2018; 9(24): 16988 doi: 10.18632/oncotarget.24769
7
Yong Zhan, Fubo Zhou, Xiaoling Yu, Fei Luo, Fangyi Liu, Ping Liang, Zhigang Cheng, Zhiyu Han, Jie Yu. Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablationInternational Journal of Hyperthermia 2018; 35(1): 105 doi: 10.1080/02656736.2018.1483533
8
André C. Teixeira, Ivelise R.C. Brasil, Alba F.C. Torres, Fabio Tavora. The Evaluation of Angiogenesis Markers in Hepatocellular Carcinoma and Precursor Lesions in Liver Explants From a Single InstitutionApplied Immunohistochemistry & Molecular Morphology 2018; 26(5): 330 doi: 10.1097/PAI.0000000000000426
9
Hongli Yu, Yuping Bai, Xiaoyu Xie, Yuemin Feng, Yao Yang, Qiang Zhu. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysisBMJ Open 2022; 12(6): e052294 doi: 10.1136/bmjopen-2021-052294